Exicure (XCUR) Interest & Investment Income (2019 - 2025)
Exicure's (XCUR) quarterly Interest & Investment Income came in at -$9000.0 in Q4 2025, down 1000.0% YoY from $1000.0 in Q4 2024, and down 131.03% on a QoQ basis from $29000.0 in Q3 2025.
Exicure (XCUR) Interest & Investment Income (2019 - 2025) Analysis & Trends
Exicure (XCUR) has 7 years of Interest & Investment Income data on file, last reported at -$9000.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 1000.0% year-over-year to -$9000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $24000.0 (up 140.0% YoY) and the FY2025 annual result came in at $29000.0, up 262.5% from the prior year.
- Interest & Investment Income retreated to -$9000.0 in Q4 2025, from $29000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $88000.0 in Q1 2021 to a low of -$9000.0 in Q4 2025.
- A 5-year average of $11250.0 and a median of $4000.0 in 2022 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 2800.0% in 2025, down 1000.0% in 2025.
- Tracing XCUR's Interest & Investment Income over 5 years: stood at $2000.0 in 2021, then jumped by 300.0% to $8000.0 in 2022, then slumped by 50.0% to $4000.0 in 2023, then slumped by 75.0% to $1000.0 in 2024, then plunged by 1000.0% to -$9000.0 in 2025.
- The last three Interest & Investment Income figures came in at -$9000.0 (Q4 2025), $29000.0 (Q3 2025), and $4000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 43,000.00 |
| Mar 31, 2021 | 88,000.00 |